|
Positron Emission Tomography in Patients with Breast Cancer Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Positron Emission Tomography in Patients with Breast Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Positron Emission Tomography in Patients with Breast Cancer Clinical research trials and Positron Emission Tomography in Patients with Breast Cancer healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Positron Emission Tomography in Patients with Breast Cancer. Positron Emission Tomography in Patients with Breast Cancer Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Positron Emission Tomography in Patients with Breast Cancer clinical trial. Human subjects often obtain the finest healthcare possible for their Positron Emission Tomography in Patients with Breast Cancer condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Positron Emission Tomography in Patients with Breast Cancer  Positron Emission Tomography in Patients with Breast Cancer
Positron Emission Tomography in Patients with Breast Cancer
For Condition: Breast Neoplasms
Status: Completed
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: This is a prospective study evaluating the role of Positron Emission Tomography (PET scan) in breast cancer. The radiopharmaceutical [18F] 2-deoxyglucose will be used as both an imaging modality and to evaluate tumor metabolism in patients with breast cancer. Patients with stage II, stage IIIA or IIIB, or stage IV breast cancer and evaluable disease in the breast and/or at metastatic sites will be studied. Patients will be injected intravenously with [18F]2-deoxyglucose and a PET scan conducted over 90 minutes. Examination of the role of PET scan in assessing the response of breast cancer to chemotherapy, especially in stage II and stage III patients, will be done. Up to three PET scans within one year may be performed. Findings by PET scan will be correlated both with those of concurrent imaging techniques (x-ray, CT scan, MRI, bone scan or mammogram), and with histologic, biochemical, and flow cytometric information on the tumor, and with findings in subsequent surgical specimens. Changes in tumor glucose metabolism with treatment will be assessed by PET imaging studies and by biochemical methods when possible.
Details: This is a prospective study evaluating the role of Positron Emission Tomography (PET scan) in breast cancer. The radiopharmaceutical [18F] 2-deoxyglucose will be used as both an imaging modality and to evaluate tumor metabolism in patients with breast cancer. Patients with stage II, stage IIIA or IIIB, or stage IV breast cancer and evaluable disease in the breast and/or at metastatic sites will be studied. Patients will be injected intravenously with [18F]2-deoxyglucose and a PET scan conducted over 90 minutes. Examination of the role of PET scan in assessing the response of breast cancer to chemotherapy, especially in stage II and stage III patients, will be done. Up to three PET scans within one year may be performed. Findings by PET scan will be correlated both with those of concurrent imaging techniques (x-ray, CT scan, MRI, bone scan or mammogram), and with histologic, biochemical, and flow cytometric information on the tumor, and with findings in subsequent surgical specimens. Changes in tumor glucose metabolism with treatment will be assessed by PET imaging studies and by biochemical methods when possible.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Histologically proven invasive carcinoma of the breast. Patients with stage II, stage IIIA or IIIB, or stage IV breast cancer who have not received local therapy to the breast or axillary lymph nodes. Evaluable tumor, either gross or microscopic, at locoregional and/or distant sites. No current pregnancy. No second invasive malignancy in addition to breast cancer. No significant concurrent medical disorders (cardiac, renal, hepatic).
Total Enrollment: 75
Location and Contact Information:
National Cancer Institute (NCI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 940151; 94-C-0151
Study Start Date: May 13, 1994
Record last reviewed: May 26, 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001385
Other Breast Neoplasms Studies:
1. Massage Therapy for Cancer-Related Fatigue
2. Mistletoe Extract and Gemcitabine for the Treatment of Solid Tumor Cancers
3. An investigational drug (CAL) versus zoledronic acid (Zometa®) in patients with breast cancer
4. OSI-774 to Treat Advanced Breast Cancer
5. Comparison of Nolvadex 20 mg and placebo combination to Nolvadex 20 mg and ZD1839 (IRESSA™) 250 mg combination in patients with metastatic breast cancer and estrogen receptor (ER) and/or progesterone (PR) positive tumours
Related Studies:
Other Breast Neoplasms Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Positron Emission Tomography in Patients with Breast Cancer
|
|
|
|
|
|
|
|
